This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

trusted source


Using mice with humanized immune systems to test cancer immunotherapies

Mice with humanized immune systems to test cancer immunotherapies
Currently developed cancer immunotherapies modify the interaction of cancer cells and the immune system, making drug testing targeting human cancer outside of clinical trials difficult. Kobe University immuno-oncologist SAITO Yasuyuki and his team developed a mouse model with a humanized immune system. With this they successfully tested a new therapeutic approach in which immune cells that protect cancer cells get activated to attack them, by disabling the immune cells' recognition system for cells belonging to the own body. Credit: SAITO Yasuyuki (Illustration created with

Mice with human immune cells are a new way of testing anti-cancer drugs targeting the immune system in pre-clinical studies. Using their new model, a Kobe University research team successfully tested a new therapeutic approach that blindfolds immune cells to the body's self-recognition system and so makes them attack tumor cells.

Cancer cells display structures on their surface that identify them as part of the self, and thus prevent them from being ingested by macrophages, a type of immune cell. Cancer immunotherapy aims at disrupting these recognition systems.

Previous studies have shown that a substance that blinds macrophages to one of these identifiers, called CD47, by disabling their CD47-scanning structure known as SIRPĪ±, can activate the cells to fight the tumor when given in combination with therapeutic cancer-targeting antibodies such as Rituximab. However, because this approach is so specific to the self-identification of human cells, until now it could only be tested in humans or monkeys, making pre-clinical studies in mice impossible.

To overcome this, Kobe University immuno-oncologist Saito Yasuyuki and his team built on their experience with creating mouse immunological models and transplanted parts of the human immune system into mice.

He says, "Studies using mouse models with humanized immune systems have focused on lymphocytes, a type of immune cell relevant to infectious diseases. The special aspect of our approach is that our new mouse model focuses on macrophages because we want to target them for the development of new cancer immunotherapies."

This enabled the researchers to both create a more fully functioning mouse model of human cancer and test the effectiveness of the blindfolding approach for the first time in this environment.

Their results, published in the journal Frontiers in Immunology, showed that the macrophage-targeted therapy indeed induced an effective cancer response. However, Saito explains, "The most exciting aspect of this result is that this approach not only promotes the engulfment (ingestion) of by macrophages but also reprograms tumor-associated macrophages, one of the current topics of cancer immunotherapy."

The immune system has an ambiguous role in the development of and fight against cancer. On the one hand, it can recognize and fight them. On the other hand, macrophages also associate with tumors, both supporting their growth and suppressing other anti-tumor immune responses. To turn these cells against cancer is the novel approach that the Kobe University researchers could now help propel forward with their new humanized mouse model.

But the result has a broader relevance, too. Saito says, "There were no suitable preclinical in vivo models to develop therapeutics targeting human surrounding tumors, so new approaches had to be tested directly on patients. I believe our model perfectly fills the gap and may help in the selection of the most effective treatment from several candidates for therapeutics targeting . The long-term goal of my project is to develop a humanized that faithfully represents the immune response against the tumor."

More information: Preclinical evaluation of the efficacy of an antibody to human SIRPĪ± for cancer immunotherapy in humanized mouse models, Frontiers in Immunology (2023). DOI: 10.3389/fimmu.2023.1294814

Journal information: Frontiers in Immunology
Provided by Kobe University
Citation: Using mice with humanized immune systems to test cancer immunotherapies (2023, December 14) retrieved 12 June 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Cancer stem cells trigger macrophage aging in mouse study


Feedback to editors